Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Moderna Stock a Buy?


Share prices of (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S 500 index. The biotech, renowned for its pioneering development of vaccines based on messenger RNA (mRNA), has struggled to manage weak sales of COVID-19 vaccine and sluggish market adoption of its new shot for respiratory syncytial virus (RSV). The stock sell-off has continued into 2025, with shares already falling 18% year to date, on the heels of the company slashing its full-year revenue guidance.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound.

Let's discuss the pros and cons of buying Moderna stock.

Continue reading


Source Fool.com

Moderna Inc. Stock

€21.55
0.620%
The Moderna Inc. stock is trending slightly upwards today, with an increase of €0.14 (0.620%) compared to yesterday's price.
Currently there is a rather positive sentiment for Moderna Inc. with 23 Buy predictions and 8 Sell predictions.
Based on the current price of 21.55 € the target price of 107 € shows a potential of 396.52% for Moderna Inc. which would more than double the current price.
Like: 0
Share

Comments